Skip to main content
SpringerLink
Log in

First-line imatinib mesylate worth it in CML

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

First-line imatinib mesylate worth it in CML. Pharmacoecon. Outcomes News 403, 3–5 (2003). https://doi.org/10.1007/BF03275959

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03275959

Keywords

Search

Navigation